Detalles de la búsqueda
1.
Global chemical effects of the microbiome include new bile-acid conjugations.
Nature
; 579(7797): 123-129, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32103176
2.
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials.
Gastroenterology
; 2024 May 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38788861
3.
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Lancet
; 401(10383): 1159-1171, 2023 04 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36871574
4.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med
; 385(14): 1280-1291, 2021 09 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34587385
5.
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
Clin Gastroenterol Hepatol
; 22(1): 144-153.e2, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37391056
6.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Gastroenterology
; 165(6): 1443-1457, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37659673
7.
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
Am J Gastroenterol
; 2024 Jan 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38095692
8.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Lancet
; 399(10342): 2200-2211, 2022 06 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35691323
9.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644155
10.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644154
11.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Lancet
; 399(10341): 2113-2128, 2022 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644166
12.
Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data.
Clin Gastroenterol Hepatol
; 21(5): 1348-1350, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35245701
13.
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
Clin Gastroenterol Hepatol
; 21(10): 2616-2628.e7, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36623678
14.
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Gastroenterology
; 162(6): 1650-1664.e8, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35134323
15.
Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
Clin Gastroenterol Hepatol
; 21(1): 173-181.e5, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644340
16.
Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
Clin Gastroenterol Hepatol
; 21(9): 2359-2369.e5, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36343846
17.
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
Gastroenterology
; 162(2): 495-508, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34748774
18.
Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study.
Gastroenterology
; 163(6): 1555-1568, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35963369
19.
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Gastroenterology
; 162(7): 1891-1910, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35227777
20.
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
Gastroenterology
; 162(7): 1876-1890, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35122766